If you do not have user and password contact us

About us

Lofarma is a leading pharmaceutical company performing research, development, production and marketing activities in the field of specific immunotherapy and diagnostics for the treatment and prevention of allergic diseases.

In obedience to Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP) and Pharmaceutical Inspection Convention (PIC) rules, Lofarma performs, in compliance with the highest quality standards, all research, development, production and marketing phases of its products in Italy and abroad for the treatment of allergic diseases.

Lofarma, based in Milan, is also present abroad with representatives in Portugal, Germany, Greece, Albania, Hungary, Mexico, South Korea and, recently, also in the Russian federation and Spain.

In order to respond effectively to this growing need, Lofarma develops, produces and markets Allergy Immunotherapies, Allergy Diagnosis, Allergy Prevention, Branded Pharmaceuticals. In short, Lofarma Product Portfolio offers a wide panel of products mainly focused on Allergy, from prevention, to the diagnosis and, which is more important, to the aethiological treatment, the allergy specific immunotherapy.


What is Pharmacovigilance?
Pharmacovigilance is defined by WHO as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem"

What is an adverse effect?
An adverse effect (or adverse reaction) is a response to a medicinal product which is noxious and unintended.

By reporting suspect adverse reactions you can help provide more information on the safety of medicines. 

The reporting can be done by everyone, patients or healthcare professionals (doctors, pharmacists, nurses, etc.). Talk to your  doctor  or pharmacist or nurse to know how you can report a suspect adverse reaction or contact your Health Authorities or your Drug Agency.
If you wish to contact the Pharmacovigilance Department of LOFARMA S.p.A., you can send an email to: